NASDAQ:ABVX Abivax Q2 2026 Earnings Results & Report $88.15 -0.90 (-1.01%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$88.08 -0.07 (-0.07%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Abivax missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released September 21, 2026. The company reported EPS of -$1.71 versus the -$0.9170 consensus estimate, while revenue of $1.37 million topped the $0.80 million estimate by $0.57 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateSeptember 21, 2026TimeAfter Market ClosesConference Call4:05 PM ET Abivax EPS ResultsActual EPS-$1.71Consensus EPS -$0.9170Beat/MissMissed by -$0.7930One Year Ago EPSN/AEPS Beat Rate3 of last 4 quartersAbivax Revenue ResultsActual Revenue$1.37 millionExpected Revenue$0.80 millionBeat/MissBeat by +$571.68 thousandYoY Revenue GrowthN/AUpcoming EarningsAbivax's Q3 2026 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Monday, December 14, 2026 at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress ReleaseInterim report Abivax Q2 2026 Earnings FAQ Did Abivax beat earnings estimates for Q2 2026? Abivax (NASDAQ:ABVX) reported earnings of -$1.71 per share for Q2 2026, missing the consensus estimate of -$0.9170. The report was announced on Monday, September 21, 2026. What was Abivax's revenue for Q2 2026? Abivax reported revenue of $1.37 million for Q2 2026, against a consensus estimate of $0.80 million. When is Abivax's next earnings date? Abivax's next earnings date is estimated for Monday, December 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for Abivax on the company's earnings history page. Abivax Earnings HeadlinesAbivax (NASDAQ:ABVX) Shares Down 5.1% - Here's What HappenedOctober 3, 2026 | americanbankingnews.comAbivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026September 30, 2026 | markets.businessinsider.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical OfficersSeptember 26, 2026 | finance.yahoo.comABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?September 26, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and NewAmsterdam Pharma Company (NAMS)September 23, 2026 | theglobeandmail.comSee More Abivax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email. Email Address About AbivaxAbivax (NASDAQ:ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. The company’s lead investigational product is obefazimod, an oral small-molecule treatment being developed for ulcerative colitis, a chronic inflammatory disease of the colon. Obefazimod, formerly known as ABX464, is designed to increase levels of microRNA-124, a molecule involved in regulating inflammatory responses. Abivax is evaluating the therapy in late-stage clinical studies for ulcerative colitis and has also investigated its potential in other inflammatory conditions, including Crohn’s disease. Founded in 2013 and headquartered in Paris, France, Abivax conducts its development activities through international clinical programs and serves the global biopharmaceutical market. The company is led by Marc de Garidel, who serves as chief executive officer and chairman of the board. Abivax’s American depositary shares trade on the Nasdaq Global Select Market under the symbol ABVX.View Abivax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
